Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

177 results about "Cell toxicity" patented technology

Cellular toxicity is a reference to any cell state that is not conducive to healthy cell function typically caused by toxicity or substances toxic to cells and resulting in cell damage.

Bionic ferroptosis nanoparticles loaded with superparamagnetic iron oxide nanoparticles as well as preparation method and application of bionic ferroptosis nanoparticles loaded with superparamagnetic iron oxide nanoparticles

The invention relates to bionic ferroptosis nanoparticles loaded with superparamagnetic iron oxide nanoparticles as well as a preparation method and application of the bionic ferroptosis nanoparticles. The biomimetic ferroptosis nano-particles are obtained by loading the superparamagnetic iron oxide nano-particles packaged by the biomimetic platelet membrane, Erastin and lactate oxidase together, and are used for guiding magnetic resonance imaging and inducing tumor cell ferroptosis. According to the method, ferroptosis is induced through Erastin, lactic acid is removed through lactate oxidase, and ferroptosis is enhanced. In addition, lactic acid is oxidized to generate hydrogen peroxide, the hydrogen peroxide is converted into cytotoxic hydroxyl radicals, and cell death is further accelerated. When the PM-ESLNP is combined with an alphaPD-L1 immunotherapy, the PM-ESLNP obviously inhibits tumor growth and metastasis in a liver cancer mouse model, and the result exceeds that of a single immunotherapy. In addition, the superparamagnetic nanoparticles in the PM-coated ESLNP can be used for carrying out real-time MRI (Magnetic Resonance Imaging) monitoring on the treatment effect. According to the invention, a groundbreaking MRI guiding method is introduced, so that ferroptosis of tumors can be enhanced and tumor immunotherapy can be synergistically improved.
Owner:LISHUI CENT HOSPITAL

Specific sequence nucleic acid molecule and application thereof as PDRN

The invention provides a specific sequence nucleic acid molecule and application thereof as a PDRN, and relates to the technical field of biology. A novel nucleic acid molecule with a specific sequence is obtained, and the sequence has certainty, biological activity and stable product quality. The PDRN of the specific sequence does not have cytotoxicity, is high in safety and has a wide application prospect. Moreover, compared with the extracted PDRN, the PDRN with a specific sequence is found for the first time, the product has a remarkable effect of promoting VEGF expression, cell damage can be effectively repaired, and a novel skin-care and repairing functional component is provided for the industries of cosmetics and medicines. The invention further provides a preparation method of the PDRN with the specific sequence, and the preparation method is simple and suitable for popularization, application and industrial production.
Owner:BLOOMAGE BIOTECHNOLOGY CORP LTD

Method for inhibiting generation of vomitoxin from bacillus cereus

The invention discloses a method for inhibiting production of vomitoxin from bacillus cereus, which is characterized in that isoleucine is added into a substance needing to inhibit production of vomitoxin from bacillus cereus, preferably 5-20mM of isoleucine is added. According to the present invention, the content of the toxin is detected through the liquid chromatography-mass spectrometry, and the cytotoxicity experiment verification results show that the isoleucine can significantly inhibit the synthesis of the vomitoxin of the bacillus cereus in the culture medium and the matrix, and can effectively reduce the toxic effect of the toxin on HeLa cells; the invention provides a safe and efficient biological control means which is suitable for various food systems such as starch food, dairy products, meat products and the like. Isoleucine can be used as a novel non-toxic and harmless food additive and is low in cost; the use method is simple, the output of vomitoxin can be reduced by directly adding a trace amount of isoleucine, and the food flavor is not affected.
Owner:JINAN UNIVERSITY

Composite hydrogel for tissue repair as well as preparation method and application thereof

The invention relates to composite hydrogel for tissue repair as well as a preparation method and application of the composite hydrogel. The composite hydrogel is prepared from a methacrylated acellular matrix, nano clay (LAP), a photoinitiator, carboxymethyl chitosan (CMCS) and water. The acellular matrix is modified through methylacryloylation, and a polymer network is reinforced by combining nano-clay, so that the mechanical strength is improved; and carboxymethyl chitosan adjusts the degradation rate, constructs a pore structure and endows antibacterial and anti-inflammatory functions. The preparation method comprises the following steps: dissolving the methacrylated acellular matrix in the PBS containing the photoinitiator, dissolving the carboxymethyl chitosan in ultrapure water, mixing, and carrying out illumination cross-linking curing. When the composite hydrogel is applied to small intestine tissue engineering, a small intestine defect part can be filled with the composite hydrogel, photo-crosslinking curing is performed to form a stent, the degradation period is matched with the small intestine regeneration period, and the antibacterial rate is gt; the cell toxicity is 0 level, a good microenvironment can be provided for cells, tissue repair can be promoted, and the compound can also be used for preparing pharmaceutical compositions for treating small intestine related diseases.
Owner:YICHU (HANGZHOU) MEDICAL TECHNOLOGY CO LTD

Materials and methods for treating cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for modulating (e.g., increasing or decreasing) an interleukin-1 (IL-1) signaling pathway (e.g., an IL-1βsignaling pathway) during an adoptive cell therapy (e.g., a chimeric antigen receptor (CAR) T cell therapy) are provided. In some cases, one or more inhibitors of an interleukin-1 receptor antagonist (IL-1RA) polypeptide can be used to increasing IL-1 signaling (e.g., to reduce immunosuppression of the administered cells). In some cases, CAR T cells having a reduced level of an interleukin 1 receptor, type I (IL-1R1) polypeptide can have decreased IL-1 signaling (e.g., to reduce T cell toxicity associated with the administered cells).
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Tetrandrine ferulate and its application in preparing medicine for treating pulmonary fibrosis

The invention discloses a tetrandrine ferulate and its application in the preparation of a medicament for treating pulmonary fibrosis. The pharmacological effects of tetrandrine and ferulic acid, as well as those after salification, are studied. It is found that both have an anti-pulmonary fibrosis effect, and the two can be used in combination to synergistically exert a more excellent anti-pulmonary fibrosis efficacy. At the same time, the solubility of tetrandrine can also be increased. This has not been reported in existing literature. The tetrandrine ferulate of the present invention has lower cytotoxicity, and the cell viability of normal human liver cells LO-2 and human embryonic fibroblasts MRC-5 is higher than that of tetrandrine, which alleviates the burden of liver and lungs to a certain extent and has good safety.
Owner:INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES

Small organic molecule fluorescent probe for lithium ion detection as well as synthesis method and application of small organic molecule fluorescent probe

The invention belongs to the technical field of fluorescent probes and supramolecules, and particularly relates to an organic small molecule fluorescent probe for lithium ion detection as well as a synthesis method and application of the organic small molecule fluorescent probe. Aiming at the problems that an existing fluorescent probe for identifying Li < + > is easily influenced by pH and interfered by coexisting metal ions, and is poor in water solubility, low in sensitivity, poor in selectivity and the like, the crown ether fluorescent molecular probe for detecting the lithium ions is 4-aza-12-crown-4-ether-7-nitrobenzofuran; the compound is prepared from 4-chloro-7-nitrobenzofuran and aza 12-crown-4-ether in a substitution manner. The fluorescent probe has the advantages that 1) the structure is simple, the preparation is easy, and excitation and emission wavelengths are in a visible light region; 2) good water solubility is achieved; 3) the material has good selectivity on lithium ions; 4) the method has the advantages of high sensitivity, quick response and the like in lithium ion detection, and can be used for in-situ-real-time detection of lithium ions; and (5) the cell toxicity is low, and the biocompatibility is good.
Owner:JINZHONG UNIV

Metal organic coordination network material as well as preparation method and application thereof

PendingCN119139259Agood choice toxicityhigh activityOrganic active ingredientsAntinoxious agentsTumour metabolismPhosphorylation
A preparation method of the metal organic coordination network comprises the following steps: respectively dissolving copper acetate and polyphenol in deionized water or dimethyl sulfoxide to form a copper acetate solution and a polyphenol solution, then dropwise adding the copper acetate solution into the polyphenol solution, introducing nitrogen, and carrying out a heating reaction to obtain a reaction mixture; centrifuging the reaction mixture to obtain a precipitation product metal organic coordination network; the metal organic coordination network is applied to preparation of a material for targeted killing of hypoxic tumor cells. The metal organic coordination network disclosed by the invention is good in dispersity, high in biocompatibility and good in hypoxic tumor cell selective toxicity. After being degraded by glutathione, the glutathione derivative has good peroxidase activity, can catalyze hydrogen peroxide to generate hydroxyl free radicals with stronger cytotoxicity, and can be used for converting tumors into oxidative phosphorylation metabolic pathways by inhibiting hypoxic tumor glycolysis and remodeling hypoxic tumor metabolism, promoting tumor cells to generate ROS (reactive oxygen species), and further improving the activity of glutathione. And the sensitivity of hypoxic tumors to copper death is enhanced.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Temperature-sensitive antibacterial hydrogel based on copper nanoparticles with ultra-small particle size and preparation method of temperature-sensitive antibacterial hydrogel

The invention discloses temperature-sensitive antibacterial hydrogel based on ultra-small-particle-size copper nanoparticles and a preparation method of the temperature-sensitive antibacterial hydrogel, and relates to the technical field of biomedical materials. The preparation method of the temperature-sensitive antibacterial hydrogel comprises the step of uniformly mixing the gel matrix, the stabilizer, the pH buffer solution and the ultra-small-particle-size copper nanoparticles to prepare the temperature-sensitive antibacterial hydrogel. The preparation method of the copper nanoparticles with the ultra-small particle size comprises the following steps that lactoferrin is dissolved in water, copper sulfate pentahydrate is added, an alkali solution is added to adjust the pH of the solution to be 8-14, then a reducing agent is added for a reaction, dialysis and drying treatment are conducted, and the copper nanoparticles with the ultra-small particle size are obtained. The hydrogel has good injectability, can release the copper nanoparticles under specific conditions and rapidly sterilize, in addition, the hydrogel is convenient to synthesize and simple to operate, has good biocompatibility, shows relatively low cytotoxicity to cells, and has relatively great application potential in the process of treating skin wound infection.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

Use of compound in treatment of liver diseases

PCT designated stage expiredWO2025039937A1Digestive systemPharmaceutical delivery mechanismDiseaseMetastatic liver cancer
Use of a compound in the treatment of liver diseases. Experimental results show that the compound has a relatively high liver-tissue-targeting property, very low toxicity to liver primary cells and high liver safety, has significant efficacy on liver diseases such as viral hepatitis (e.g., hepatitis B) and liver cancers (including primary liver cancers and metastatic liver cancers), and has relatively good physicochemical properties, metabolic stability, bioavailability and safety, thus having very good drug development prospects.
Owner:BEIJING SYNTHETIC VACCINE BIOSCIENCES CO LTD

Application of compound in treatment of liver diseases

PendingCN119499255ADigestive systemPharmaceutical delivery mechanismDiseaseMetastatic liver cancer
The invention discloses application of a compound in treatment of liver diseases. Experimental results show that the compound has relatively high liver tissue targeting property, very low toxicity to liver primary cells, high liver safety and obvious curative effects on liver diseases such as viral hepatitis (such as hepatitis B), liver cancer (including primary liver cancer and metastatic liver cancer) and the like; in addition, the compound also has better physicochemical properties, metabolic stability, bioavailability and safety, and has a very good drug development prospect.
Owner:BEIJING SYNTHETIC VACCINE BIOSCIENCES CO LTD

Genome insertions in cells

The present disclosure provides compositions and methods for inserting heterologous payload sequences into a target-site in a host cell genome. The compositions and methods use non-LTR retrotransposon reverse transcriptase proteins that bind template RNAs comprising a payload sequence that encodes a protein or regulatory RNA. The template RNA can comprise modified uridines that are not cleavable by a ribozyme. The incorporation of modified uridines increases the efficiency of integration and expression of the payload sequence and decreases cellular toxicity.
Owner:ADDITION THERAPEUTICS INC

Film-embedded conjugated oligomeric electrolyte based on natural product, and preparation method and application of film-embedded conjugated oligomeric electrolyte

The invention discloses a film-embedded conjugated oligomeric electrolyte based on a natural product, and the structure of the film-embedded conjugated oligomeric electrolyte takes a natural polyphenol compound as a conjugated skeleton part, so that the overall biocompatibility of molecules is improved, and the toxicity is reduced; alkyl chains with different lengths or numbers are used as side chain parts to adjust the compatibility with a cell membrane and promote the membrane embedding and retention of molecules, and the alkyl chains can disturb the phospholipid arrangement of the cell membrane and increase the membrane permeability after the molecules are embedded into the membrane; a positively charged group is used as an end group part, and a negatively charged cell membrane is anchored through electrostatic attraction, so that the local molecular concentration is improved. The cell membrane is modified by the embedded membrane conjugated oligomeric electrolyte derived from the natural product, so that the permeability of the cell membrane is improved, the cytotoxicity is reduced, and the catalytic efficiency of cells is improved. The cell membrane is modified by the embedded membrane conjugated oligomeric electrolyte derived from the natural product, so that the permeability of the cell membrane is improved, the cytotoxicity is reduced, and the catalytic efficiency of cells is improved.
Owner:NINGBO INST OF MATERIALS TECH & ENG CHINESE ACAD OF SCI +1

Specific sequence nucleic acid molecules and their applications as PDRN

This invention provides specific sequence nucleic acid molecules and their applications as PDRNs, relating to the field of biotechnology. This invention yields novel specific sequence nucleic acid molecules with deterministic sequences, stable biological activity, and stable product quality. The PDRNs with these specific sequences are non-cytotoxic, exhibit high safety, and have broad application prospects. Furthermore, this invention is the first to discover that specific sequence PDRNs, compared to extracted PDRNs, significantly promote VEGF expression and effectively repair cell damage, providing a novel skincare and repair ingredient for the cosmetics and pharmaceutical industries. This invention also provides a simple method for preparing specific sequence PDRNs, suitable for widespread application and industrial production.
Owner:BLOOMAGE BIOTECHNOLOGY CORP LTD

Dual inhibitors for the treatment of alzheimer's disease

Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula —[CH2]n— with n=0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.
Owner:UNIV DE BARCELONA +1

A cleavage module, system for escherichia coli self-cleavage and application thereof

The application relates to a lysis module for E. coli autolysis, a system and application thereof, relates to the field of E. coli autolysis, and the lysis module is SP-lysozyme-SsrA, the SP is a nucleotide sequence for coding a signal peptide, the amino acid sequence of the SsrA degradation label is SEQ ID NO:8, the nucleotide sequence of the lysozyme is SEQ ID NO:1, the SP is fused at the N-terminal of the lysozyme, and the SsrA is fused at the C-terminal of the lysozyme. By adopting a simpler and more efficient mode to assist lysozyme in the cytoplasm to enter the periplasmic space, the number of lysis modules is reduced to reduce the metabolic burden caused to host cells; meanwhile, the problem of lysis module leakage expression is solved, cell toxicity is reduced, and the biomass of host cells and the yield of target proteins are improved.
Owner:BEIJING UNIV OF CHEM TECH

Organic small molecules for reducing copper overload toxicity and their applications

ActiveCN121466044BMetabolism disorderHydroxy compound active ingredientsCopper ChelatorCation Pump
This invention belongs to the field of pharmaceutical technology and discloses small organic molecules for reducing copper overload toxicity and their applications. Specifically, it discloses four small organic molecules for reducing copper overload toxicity and methods for doing so. These four small organic molecules are not copper chelators and do not reduce intracellular copper levels, thus not affecting the activity of copper-related enzymes. Furthermore, these four small organic molecules are not copper ion transporters and do not transport copper into cells, thus not exacerbating the cytotoxicity of copper overload.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

A method for preparing and using a mesenchymal stem cell protective agent composition

The application relates to a preparation method and application method of a mesenchymal stem cell protective agent composition, and relates to the technical field of stem cell treatment, in particular to a protective agent composition, a preparation technology of the protective agent composition and an application technology of the protective agent composition in mesenchymal stem cell treatment. The application solves the problems of insufficient cell stemness maintenance, complex formula or cell toxicity in the existing mesenchymal stem cell cryopreservation. The protective agent composition prepared by the preparation method comprises a deferoxamine pretreatment protective agent and a sodium lactate Ringer injection storage solution. The application method inhibits low-temperature-induced ferroptosis through DFO pretreatment, so that the mesenchymal stem cells can still maintain the multi-directional differentiation potential, the immunoregulatory function and the proliferation ability after being treated at 4 DEG C for 24-48 hours, the serum or complex nutritional ingredients do not need to be added, and the protective agent composition has the advantages of clear composition, high safety, simple operation and the like. The application is suitable for the fields of stem cell treatment, regenerative medicine, pet medical treatment and the like.
Owner:YANBIAN UNIV

Construction method of indigo blue producing strain and application of indigo blue producing strain in indigo blue production

The invention belongs to the technical field of synthetic biology and fermentation engineering, and discloses an engineering bacterium for producing Indigoidine based on membrane vesicle engineering reinforced corynebacterium glutamicum and application of the engineering bacterium. According to the invention, the ncp1 gene of corynebacterium glutamicum is knocked out through a CRISPR-Cas12a gene editing technology, connection between cell walls and cell membranes is relieved, and a chassis strain of high-yield extracellular membrane vesicles (OMVs) is constructed; meanwhile, a recombinant expression vector is introduced, indigo synthetase BpsA is positioned and displayed on membrane vesicles by utilizing PorB anchoring protein, and activating enzyme Sfp is co-expressed. In fermentation production, a staged feeding and IPTG (isopropyl-beta-d-thiogalactoside) and Tween-80 dual induction strategy is adopted to promote thalli to express zymoprotein and release a large number of membrane vesicles at the same time. According to the method, the membrane vesicles are used as an extracellular microreactor, so that the'simultaneous synthesis and secretion 'of the indissolvable indigo is realized, the problems of cytotoxicity and metabolic inhibition caused by intracellular precipitation of the product are effectively solved, and the yield and extraction efficiency of the indigo are remarkably improved.
Owner:ZENO FUTURE BIOTECHNOLOGY (QINGDAO) CO LTD

Application of PAD4 inhibitor to preparation of medicine for preventing and treating peripheral neuropathy caused by chemotherapy medicine

The invention provides application of a PAD4 inhibitor to preparation of a medicine for preventing and treating peripheral nerve injury caused by chemotherapy medicines. Experiments find that the PAD4 inhibitor has a protective effect on peripheral nerve cell toxicity caused by chemotherapeutic drugs, and particularly has a protective effect on neurotoxicity of ND7 / 23 cells induced by oxaliplatin; on an animal model, the PAD4 inhibitor has a protective effect on oxaliplatin-induced mouse peripheral neurotoxicity. The PAD4 inhibitor can be used as an adjuvant of a chemotherapeutic drug for cancer treatment, and has an effect of relieving neurotoxicity caused by chemotherapy.
Owner:NANJING UNIV OF TRADITIONAL CHINESE MEDICINE +1

Application of aromatic hydrocarbon receptor stimulant in preparation of medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation

The invention discloses application of an aromatic hydrocarbon receptor stimulant in preparation of a medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation, and belongs to the field of biological medicine. According to the present invention, with the PAS-B structural domain of the AHR as the target, the virtual screening technology, the target verification test and the weaned piglet diarrhea pharmacodynamic evaluation test are performed to determine the arctigenin as the AHR strong agonist and the anti-inflammatory drug, and the arctigenin has the good treatment effect on the weaned piglet diarrhea. Experimental results show that 10 mg / kg of arctigenin can significantly relieve diarrhea and hemafecia symptoms of weaned piglets, reduce the content of inflammatory factors in serum and intestinal tissues and improve the intestinal structure of weaned piglets, has no significant cytotoxicity, hepatorenal toxicity and intestinal epithelial cell growth inhibition effect, and can be used for preparing a feed additive for weaned piglets. The compound can be used for preparing medicines for treating diarrhea of weaned piglets. The invention provides a new raw material medicine for treating diarrhea of weaned piglets, and has great economic value and wide application prospect.
Owner:HUAZHONG AGRI UNIV

Application of rutin composition in preparation of medicine for relieving toxicity of porcine hepatocytes

The invention discloses application of a rutin composition in preparation of a medicine for relieving toxicity of porcine hepatocytes, and belongs to the technical field of medicines. The rutin composition comprises rutin, vitamin C, vitamin E, tanshinone IIA, puerarin and licochalcone B. The invention further discloses a preparation method of the rutin composition. According to verification of the embodiment of the invention, it can be obtained that the rutin composition can relieve porcine liver cell toxicity by improving IPLs cell viability, restoring zearalenone to inhibit IPLs cell proliferation and restoring zearalenone to improve ROS yield in IPLs cells.
Owner:SHANDONG AGRICULTURAL UNIVERSITY

Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors

Chimeric antigen receptor-transduced T cells (CAR-T cells) show a remarkable efficacy for some hematological malignancies. However, CAR targets are restricted to a few antigens primarily due to on-target off-tumor toxicities of CAR-T cells. Although several strategies were proposed to avoid on-target off-tumor toxicities, most of them use complicated designs including dual gene expression for specificity. In this study, we show that switchable CAR immune cells (e.g., CAR-T cells) with a tumor-targeting adaptor can mitigate on-target off-tumor toxicity against the tumor antigen that cannot be targeted with conventional CAR immune cells due to this toxicity, such as CD40 and CS1. Therefore, a switchable CAR system is a valuable tool to control CAR-T cell toxicity while maintaining therapeutic efficacy, which enables CAR anti-tumor target expansion.
Owner:SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION +1

Immunotoxicity evaluation method and application thereof

PendingCN121950988AFilling the gap in immunotoxicity evaluationSensitive immunotoxicity evaluation systemMicrobiological testing/measurementComplex mathematical operationsEnvironmental toxicologyBiochemical engineering
The invention belongs to the field of environmental toxicology and immunology, and particularly relates to an immunotoxicity evaluation method and application thereof. The method comprises the following steps: adding a target pollutant into a culture medium to obtain an exposure culture solution containing the target pollutant, incubating macrophages through the exposure culture solution containing the target pollutant, detecting the macrophages after incubation to obtain results of evaluation indexes, and performing immunotoxicity evaluation based on the results of the evaluation indexes, the target pollutants are chemicals or actual water samples; the evaluation indexes comprise basic cell toxicity, macrophage phagocytic ability and macrophage anti-infection ability. The invention provides a sensitive and reliable immunotoxicity evaluation system, and fills the blank of immunotoxicity evaluation of chemicals, especially raw water. The defects of a traditional concentration method are avoided through a direct exposure method, and the immunotoxicity of the water sample is reflected more truly. The established QSAR model provides a theoretical tool for predicting the immunotoxicity of novel chemicals.
Owner:NANJING MEDICAL UNIV